AGEN (Agenus) Institutional Ownership: 22.53% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGEN Agenus Inc AGEN
43 GF Score
Price $7.16
GF Value $3.78
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus Institutional Ownership?

Agenus AGEN -2.32% 43 Institutional Ownership is 22.53% as of Aug. 18, 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Agenus's institutional ownership is 22.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Agenus's Insider Ownership is 15.96%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Agenus's Float Percentage Of Total Shares Outstanding is 98.82%.

Agenus Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Agenus's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus Institutional Ownership Chart

Agenus Historical Data

The historical data trend for Agenus can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 13.49 13.60 12.40 12.23 12.19 11.40 11.42 11.71 19.87 18.54
AGEN
43GF Score
Agenus Inc AGEN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 22.53% mean?
Agenus (AGEN) has a Institutional Ownership of 22.53% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Agenus and its competitors.
Is Agenus' Institutional Ownership too high?
Agenus' current Institutional Ownership is 22.53%. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Institutional Ownership compare to FULC and IRD?
Agenus' Institutional Ownership of 22.53% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Agenus and its competitors. Agenus's current Institutional Ownership is 22.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current Institutional Ownership is 22.53%. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Agenus (AGEN), the current Institutional Ownership is 22.53% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agenus (AGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for AGEN:

  • Institutional Ownership: 22.53%
  • GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
  • GF Score™: 43/100 with 12 warning signs

No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agenus Business Description

Other Exchanges AJ8:Germany
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score

Get the complete analysis for AGEN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$3.78
GF Value